Authors of a post-hoc analysis reported that asenapine is effective in the management of pediatric bipolar disorder regardless of the number of prior manic or mixed episodes.
Sufficient dosing and treatment duration might be needed to assess vilazodone’s effectivness for management of symptoms among patients with GAD, concluded authors of a pooled analysis of data from three phase 3 clinical trials.
Study authors presented that most outpatients who started on aripiprazole lauroxil 882mg every 4 weeks remained for the entire year with completion rates ranging between 73.2% (oral aripiprazole) to 52.6% (oral olanzapine).
Among members of Humana’s Medicare Advantage and Prescription Drug plan who have schizophrenia, paliperidone palmitate (PP) was associated with fewer hospitalizations and ER visits than oral atypical antipsychotics (OAAs), and the resulting healthcare system savings offset half of the cost difference between PP and OAAs.
Patient assistance programs might improve patient adherence with prescribed long-acting atypical antipsychotic injectables among people with schizophrenia, according to findings from a retrospective cohort study.
Cases of baclofen-indued mania were seen in psychiatric patients receiving the drug for the mangement of tardive dyskinesia and alcohol dependence.
Up to 20 weeks of treatment with lurasidone adjunctive to lithium or valproate in patients with bipolar I disorder resulted in a “clinically significant mean improvement in depression and mania scores” during the open-label stabilization phase of a randomized study.
Levomilnacipran extended-release (ER) significantly improved overall symptoms of depression in patients with major depressive disorder (MDD) and cognitive difficulties.
Does an overdose of a selective serotonin reuptake inhibitor (SSRI) increase risk of occurrence of pancreatitis?
Lurasidone was associated with medium to large treatment effect sizes in adult patients with schizophrenia who presented with prominent positive symptoms.
Please login or register first to view this content.
